Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 8/31/2023 | 5/31/2022 | 5/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.03 | -0.06 | 0.64 |
| FCF Yield | -26.05% | -40.55% | -10.67% | -4.22% |
| EV / EBITDA | -5.76 | -4.27 | -9.93 | -29.79 |
| Quality | ||||
| ROIC | -69.94% | -59.92% | -85.08% | -24.49% |
| Gross Margin | 44.94% | 68.75% | 37.76% | 76.76% |
| Cash Conversion Ratio | 0.82 | 1.10 | 0.65 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.80% | -32.36% | 96.45% | 179.21% |
| Free Cash Flow Growth | 50.31% | -1.59% | -19.95% | 38.75% |
| Safety | ||||
| Net Debt / EBITDA | -1.42 | -0.47 | -1.14 | -0.19 |
| Interest Coverage | -4.54 | -2.12 | -9.10 | -5.39 |
| Efficiency | ||||
| Inventory Turnover | 6.34 | 1.53 | 5.82 | 6.05 |
| Cash Conversion Cycle | 102.99 | 672.84 | -77.20 | 408.22 |